Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:106904.
doi: 10.1155/2015/106904. Epub 2015 Feb 26.

The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy

Affiliations

The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy

Gabriella Moroni et al. J Immunol Res. 2015.

Abstract

Few studies have correlated serum biomarkers with renal histology, the gold standard for renal activity, in lupus nephritis (LN). We tested a panel of autoantibodies and complement at the time of kidney biopsy and after treatment. Anti-dsDNA, anti-nucleosome, anti-ribosome P, and anti-C1q antibodies and C3/C4 were measured in 107 patients with LN at the time of renal biopsy and after 6-12 months and were correlated with clinical/histological parameters. At multivariate analysis, high titers of anti-C1q antibodies or of anti-dsDNA antibodies (P = 0.005, OR = 8.67, CI: 2.03-37.3) were the independent predictors that discriminate proliferative from nonproliferative LN. All the immunological parameters, except anti-ribosome, showed a significant correlation with activity index but not with chronicity index. Only anti-C1q showed a significant correlation with the amount of proteinuria (R = 0.2, P = 0.03). None of the immunological parameters were predictive of remission at 6 and 12 months. We found that anti-C1q alone or in combination with anti-dsDNA emerged as the most reliable test in differentiating proliferative and nonproliferative LN. Anti-C1q was the only test correlated with the clinical presentation of LN. After treatment, the titre of the autoantibodies was significantly reduced, but none was predictive of remission.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cervera R., Khamashta M. A., Font J., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2003;82(5):299–308. doi: 10.1097/01.md.0000091181.93122.55. - DOI - PubMed
    1. Moroni G., Quaglini S., Maccario M., Banfi G., Ponticelli C. 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis. Kidney International. 1996;50(6):2047–2053. doi: 10.1038/ki.1996.528. - DOI - PubMed
    1. Ravirajan C. T., Rowse L., MacGowan J. R., Isenberg D. A. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systematic lupus erythematosus: a cross-sectional study. Rheumatology. 2001;40(12):1405–1412. doi: 10.1093/rheumatology/40.12.1405. - DOI - PubMed
    1. Ho A., Magder L. S., Barr S. G., Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 2001;44(10):2342–2349. doi: 10.1002/1529-0131(200110)44:10x003C;2342::aid-art397x0003e;3.0.co;2-8. - DOI - PubMed
    1. Linnik M. D., Hu J. Z., Heilbrunn K. R., et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 2005;52(4):1129–1137. doi: 10.1002/art.20980. - DOI - PubMed

Publication types